Douglas Tremblay, MD, discusses the use and potential benefits and risks of cytoreduction for patients with essential thrombocytopenia and polycythemia vera.
Douglas Tremblay, MD, assistant professor of medicine at the Icahn School of Medicine at Mount Sinai, discusses the use of cytoreductive therapy and potential benefits and risks of cytoreduction for patients with essential thrombocytopenia (ET) and polycythemia vera (PV).
According to Tremblay, the primary approach that is used to prevent thrombosis in certain disease states involves cytoreductive therapy. This is particularly true for patients at high-thrombotic-risk or patients who have symptoms that may be alleviated by such treatment.
Some of the current approved treatment options for cytoreduction in ET and PV include hydroxyurea and long-acting interferons for both, as well as anagrelide (Agrylin) for ET, and ruxolitinib (Jakafi) for PV.
Transcription:
0:10 | Cytoreductive therapy refers to multiple medications which are given with the purpose of reducing blood counts in both essential thrombocythemia and polycythemia vera, but are also given for the purpose of reducing thrombotic risk. Thrombosis is the leading cause of morbidity and mortality in patients with polycythemia vera and essential thrombocytopenia, and these medications are given in order to mitigate that risk.
0:35 | Cytoreductive therapy is given in order to reduce thrombotic risk, and that's really its purpose. It is associated with some [adverse] effects in different medications, including hydroxyurea, pegylated interferon, anagrelide for ET, or ruxolitinib for PV, [which] have unique [adverse] effect profiles, but they all carry some risks and [adverse] effects. They're not curative therapies. They are really done to reduce risk of thrombosis and therefore, it is important to understand what someone's baseline risk is for thrombosis, that way you can decide if the benefits of cytoreductive therapy outweigh the risks in those patients.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More